CHI SQUARE: Can HDL Infusions Significantly Quicken Atherosclerosis Regression A Phase II, Multi-Center, Double-Blind, Ascending Dose, Placebo-Controlled, Dose-Finding Trial of CER-001 or Placebo in Subjects With Acute Coronary Syndrome.

Trial Profile

CHI SQUARE: Can HDL Infusions Significantly Quicken Atherosclerosis Regression A Phase II, Multi-Center, Double-Blind, Ascending Dose, Placebo-Controlled, Dose-Finding Trial of CER-001 or Placebo in Subjects With Acute Coronary Syndrome.

Completed
Phase of Trial: Phase II

Latest Information Update: 11 Nov 2015

At a glance

  • Drugs CER 001 (Primary)
  • Indications Acute coronary syndromes; Atherosclerosis
  • Focus Therapeutic Use
  • Acronyms CHI SQUARE
  • Sponsors Cerenis Therapeutics
  • Most Recent Events

    • 29 Apr 2014 Primary endpoint 'Plaque-volume' has not been met according to results published in European Heart Journal.
    • 29 Apr 2014 Results published in the European Heart Journal.
    • 28 Feb 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top